Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma

Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer

(2019) Ruohua Chen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions

(2018) R I Haddad et al.   ANNALS OF ONCOLOGY

Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma

(2018) Astrid De Meulenaere et al.   HISTOPATHOLOGY

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies

(2018) Shashi Gujar et al.   OncoImmunology

2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma

(2018) Kyoichi Kaira et al.   EUROPEAN JOURNAL OF CANCER

The relationship between tumour glucose metabolism and host systemic inflammatory responses in patients with cancer: A systematic review

(2018) Ross D Dolan et al.   JOURNAL OF NUCLEAR MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies

(2018) Frank J. Ward et al.   Frontiers in Immunology

Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC

(2017) Kyoichi Kaira et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prognostic significance of PD-L1 in solid tumor

(2017) Qianqian Wang et al.   MEDICINE

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Indicators of responsiveness to immune checkpoint inhibitors

(2017) Bradley D. Shields et al.   Scientific Reports

Monitoring immune responses in the tumor microenvironment

(2016) Jennifer A Wargo et al.   CURRENT OPINION IN IMMUNOLOGY

High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma

(2016) Yih-Leong Chang et al.   EUROPEAN JOURNAL OF CANCER

Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma

(2016) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment

(2016) Mariko Hirai et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression

(2016) Terumasa Sowa et al.   Cancer Medicine

Role of EMT in Metastasis and Therapy Resistance

(2016) Bethany Smith et al.   Journal of Clinical Medicine

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

(2015) Moon-Young Kim et al.   LUNG CANCER

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer

(2015) Wenjing Zhang et al.   PLoS One

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

(2014) Vassiliki Saloura et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Wnt/β-catenin signaling enhances hypoxia-induced epithelial–mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling

(2013) Qi Zhang et al.   CARCINOGENESIS

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors

(2010) Kyoichi Kaira et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased 18F-FDG uptake and expression of Glut1 in the EMT transformed breast cancer cells induced by TGF-β

(2010) W. Li et al.   NEOPLASMA

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer

(2008) K. I. Al-Shibli et al.   CLINICAL CANCER RESEARCH